Wordt geladen...
Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice
Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...
Bewaard in:
| Gepubliceerd in: | Pharmacol Res Perspect |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753983/ https://ncbi.nlm.nih.gov/pubmed/33474802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.700 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|